LF
UTHR icon

Longbow Finance’s United Therapeutics UTHR Stock Holding History

Longbow Finance’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-11,226
Closed -$3.46M – 98
2025
Q1 		$3.46M Buy
+11,226
New +$3.85M 0.41% 66

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Longbow Finance's UTHR Position: Q2 2025 in Review

Longbow Finance sold out of United Therapeutics (UTHR) in Q2 2025, closing a stake of 11,226 shares — an estimated $3.46M sold.

Longbow Finance first reported a position in UTHR in Q1 2025 and held it in 1 quarter. The position peaked at $3.46M in Q1 2025. 670 funds tracked by Wall St. Rank hold UTHR as of Q2 2025.

  • Longbow Finance reported no remaining United Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Longbow Finance sold 11,226 United Therapeutics shares in Q2 2025, an estimated $3.46M.
  • Longbow Finance first reported a position in United Therapeutics in Q1 2025 and held it in 1 quarter.
  • Longbow Finance's United Therapeutics position peaked at $3.46M in Q1 2025.
  • 670 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2025.

Based on Longbow Finance's 13F filing for Q2 2025, filed 5 Aug 2025.